Trial Profile
A Phase III Clinical Trial to Study the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Subjects With a History of Herpes Zoster
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Varicella zoster virus vaccine live (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 07 Feb 2014 Actual end date has changed from 1 Sep.2007 to 1 Jul.2007 according to ClinicalTrials.gov record.
- 20 Apr 2010 Results reported in Vaccine.
- 01 Sep 2009 Actual initiation date changed from Apr 2006 to May 2006 as reported by ClinicalTrials.gov.